Skip to main content

19-09-2023 | Oncology | Podcast | Article | Illumina, Inc., and Eli Lilly and Company

Episode 5

Next-generation sequencing

Emerging biomarkers in thyroid and non-small cell lung cancers

Prof. Andrew Beggs

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

To delve further into the subject matter with added slides and supplementary information, we invite you to explore the video version.

00:55 – Introduction from Prof Beggs “setting the scene”
03:05 – Biopsy types for NGS
07:50 – DNA versus RNA for analysis
13:30 – Processing considerations – an NHS case study
16:20 – Integrating genomic profiling into patient care and management
22:50 – Conclusions

This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.

« Previous episode: Stem cell therapy for PD

Next episode: OCT for coronary imaging »


Related topics